Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299754 | 1.00 | CTSL (0.42) | CTSLHTR2CSLC6A4CCR5SIGMAR1 | |
| SCHEMBL13048815 | 0.90 | CTSL (0.39) | CTSLHTR2CSLC6A4CCR5L3MBTL1 | |
| SCHEMBL2622097 | 0.89 | CTSL (0.40) | CTSLHTR2CSLC6A4CCR5L3MBTL1 | |
| SCHEMBL17577847 | 0.89 | CTSL (0.38) | CTSLHTR2CSLC6A4CCR5L3MBTL1 | |
| SCHEMBL2113432 | 0.89 | CTSL (0.40) | CTSLHTR2CSLC6A4CCR5L3MBTL1 | |
| SCHEMBL2622149 | 0.88 | HSD17B10 (0.39) | CTSLHTR2CSLC6A4CCR5 | |
| SCHEMBL2117031 | 0.88 | HSD17B10 (0.39) | CTSLHTR2CSLC6A4CCR5 | |
| SCHEMBL23441259 | 0.88 | CTSL (0.44) | CTSLHTR2CSLC6A4L3MBTL1 | |
| SCHEMBL23441258 | 0.88 | CTSL (0.44) | CTSLHTR2CSLC6A4L3MBTL1 | |
| SCHEMBL29808694 | 0.86 | PDK1 (0.48) | CTSLHTR2CSLC6A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CTSL 134/4885HTR2C 4784/4885SLC6A4 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.